Access to this content is restrictedLogin with your ESMO Account
Take the CME test and receive 1 ESMO - MORA point
Login to access the resources on OncologyPRO.
- To provide an overview of the evidence on sex and gender differences in cancer incidence and outcome in selected cancer types, such as melanoma and lung
- To show gender-related differences in cancer diagnosis - melanoma as an example
- To discuss gender-related differences in treatment allocation - gastrointestinal cancers as an example
- To discuss biological, sex-related and sociocultural, gender-related differences in toxicity of anticancer therapies
In this E-Learning module, the author provides definitions of sex, a biological variable, and gender, that refers to the socially constructed characteristics of women, men, girls and boys, and elaborates in depth on the influence of sex and gender on cancer risk and outcome. Globally, men have higher cancer incidence and mortality rates, and the author explains this from both a historical and current point of view.
The author describes sex and gender related differences in survival, tumour biology and diagnosis, using the example of melanoma (better survival in women independently of stage and age), lung cancer as an example of sex-related differences in tumour biology (e.g. molecular subtype), and bladder cancer, as an example of gender-related differences in diagnosis, highlighting diagnostic delays in women.
In addition, several analyses of registry data are presented which show sex and gender differences in treatment allocation, with women receiving less often treatment with curative intent (e.g. for gastro-oesophageal cancer) with detrimental effects on the outcome.
There is also increasing interest in differences in treatment toxicity between men and women, with women experiencing higher toxicity risk for various types of treatments. The author explains a range of factors which contribute to this increased toxicity risk in women.
The author, who is a driving force of the ESMO initiative on gender medicine in oncology, advocates that more research is needed to move the field of sex- and gender-related aspects in oncology forward.
Declaration of interest
Berna Özdemir has reported:
Advisory Board, Institutional: BMS, Roche, Ipsen, MSD, Pfizer, Sanofi
Invited Speaker, Institutional: BMS, Merck, Novartis.
Other, Institutional: Janssen
Local PI, Institutional: Parexel, Seattle Genetics.